Navigation Links
New antibacterials being developed to tackle MRSA superbug

A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.

Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA.

The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat.

"The so-called superbug MRSA is fast becoming untreatable with the currently available antibiotics," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "We urgently need a new generation of antibacterial medicines to stop its spread through hospitals, nursing homes and the wider community."

The compounds being developed by Prolysis under the award from the Wellcome Trust block the ability of the MRSA bacteria to divide and multiply. They do this by inhibiting the function of the bacterium's FtsZ protein, which is essential for cell division. FtsZ is not found in humans so targeting a unique protein like this should reduce the likelihood of side-effects in patients. Because of the novel mode of action of the new class of compounds, the levels of resistance in the bacterial population should be extremely low if a new drug was to emerge from this programme.

"The antibiotic that we are developing is far more selective than those currently in use, targeting only staphylococcal infections," says Dr Lloyd C zaplewski, Director of Research at Prolysis. "Other, broad-spectrum antibiotics tend to kill the patient's natural bacteria, leaving them open to secondary infection by other pathogenic bacteria, for example Clostridium difficile."

Given the urgent need for new antibacterials to tackle staphylococcal infections, Dr Czaplewski believes that the research, supported by this £3.48 million, 33 month award, could result in a new medicine being fast-tracked into clinical evaluation by 2009.


'"/>

Source:Wellcome Trust


Related biology news :

1. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
2. When it comes to cell entry, being average has its advantages
3. Sperm stem cells closer to being like embryonic stem cells
4. Progress being made in exploring potential use of stem cells to treat heart disease
5. Nanotechnology being used to improve biocompatibility of human prosthetics and implants
6. Fat stem cells being studied as option for breast reconstruction
7. DNA layer reduces risk of reserve parts being rejected
8. Are scientists making progress in being able to regenerate bone tissue?
9. Robot-based system developed at Carnegie Mellon detects life in Chiles Atacama desert
10. Disease progression model of pancreatic cancer developed by Penn researchers
11. New HIV drug candidate developed in Sweden
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... 2017 The Global Implantable Biomaterials Market ... around 7.5% over the next decade to reach ... prominent trends that the market is witnessing include ... graft transplant surgeries and medical implants and technological ... categorized into immunomodulatory biomaterials, natural, polymers, hydrogels and ...
(Date:1/17/2017)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics company ... pathogens today announced the appointment of Mary Duseau as ... Company,s President and CEO since 2009, who will assume the position ... effective today. In addition, Ms. Duseau will join the ... ...
(Date:1/17/2017)... --  Pulmatrix, Inc . (NASDAQ: PULM ), ... to address serious pulmonary diseases, today announced that its ... of CF patients, PUR1900, has been designated as a ... & Drug Administration. Under the QIDP ... of novel drugs against important pathogens, Pulmatrix will receive ...
(Date:1/17/2017)... Research and Markets has announced the addition of ... and Companies" to their offering. ... The number of companies ... few years. More than 1,000 companies have been identified to ... are profiled in the report along with tabulation of 811 ...
Breaking Biology Technology: